Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

35,720 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Serum Concentration of CD137 and Tumor Infiltration by M1 Macrophages Predict the Response to Sintilimab plus Bevacizumab Biosimilar in Advanced Hepatocellular Carcinoma Patients.
Zhang W, Gong C, Peng X, Bi X, Sun Y, Zhou J, Wu F, Zeng H, Wang Y, Zhou H, Zhao H, Cai J, Zhou A. Zhang W, et al. Among authors: zhou h, zhou j, zhou a. Clin Cancer Res. 2022 Aug 15;28(16):3499-3508. doi: 10.1158/1078-0432.CCR-21-3972. Clin Cancer Res. 2022. PMID: 35275208 Free PMC article.
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial.
Lu S, Wu L, Jian H, Chen Y, Wang Q, Fang J, Wang Z, Hu Y, Sun M, Han L, Miao L, Ding C, Cui J, Li B, Pan Y, Li X, Ye F, Liu A, Wang K, Cang S, Zhou H, Sun X, Ferry D, Lin Y, Wang S, Zhang W, Zhang C. Lu S, et al. Among authors: zhou h. Lancet Oncol. 2022 Sep;23(9):1167-1179. doi: 10.1016/S1470-2045(22)00382-5. Epub 2022 Jul 28. Lancet Oncol. 2022. PMID: 35908558 Clinical Trial.
Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying FGFR2 fusions or rearrangements: A phase II study.
Shi GM, Huang XY, Wen TF, Song TQ, Kuang M, Mou HB, Bao LQ, Zhao HT, Zhao H, Feng XL, Zhang BX, Peng T, Zhang YB, Li XC, Yu HS, Cao Y, Liu LX, Zhang T, Wang WL, Ran JH, Liu YB, Gong W, Chen MX, Cao L, Luo Y, Wang Y, Zhou H, Yang GH, Fan J, Zhou J. Shi GM, et al. Among authors: zhou h, zhou j. Cancer Med. 2023 Feb;12(4):4137-4146. doi: 10.1002/cam4.5273. Epub 2022 Sep 20. Cancer Med. 2023. PMID: 36127767 Free PMC article. Clinical Trial.
Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2).
Xu J, Li Y, Fan Q, Shu Y, Yang L, Cui T, Gu K, Tao M, Wang X, Cui C, Xu N, Xiao J, Gao Q, Liu Y, Zhang T, Bai Y, Li W, Zhang Y, Dai G, Ma D, Zhang J, Bai C, Huang Y, Liao W, Wu L, Chen X, Yang Y, Wang J, Ji S, Zhou H, Wang Y, Ma Z, Wang Y, Peng B, Sun J, Mancao C. Xu J, et al. Among authors: zhou h. Nat Commun. 2022 Feb 14;13(1):857. doi: 10.1038/s41467-022-28408-3. Nat Commun. 2022. PMID: 35165274 Free PMC article. Clinical Trial.
Pyrazolo[1,5-a]pyrimidine TRPC6 antagonists for the treatment of gastric cancer.
Ding M, Wang H, Qu C, Xu F, Zhu Y, Lv G, Lu Y, Zhou Q, Zhou H, Zeng X, Zhang J, Yan C, Lin J, Luo HR, Deng Z, Xiao Y, Tian J, Zhu MX, Hong X. Ding M, et al. Among authors: zhou h, zhou q. Cancer Lett. 2018 Sep 28;432:47-55. doi: 10.1016/j.canlet.2018.05.041. Epub 2018 May 31. Cancer Lett. 2018. PMID: 29859875 Free PMC article.
35,720 results
You have reached the last available page of results. Please see the User Guide for more information.